Komori
General Meetings of Shareholders4552JCR Pharmaceuticals Co.,Ltd.Pharmaceuticals

Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Shareholder Meeting Materials

For the 51st Annual General Meeting of Shareholders, the Company submitted a proposal to elect 12 directors, increasing the number of directors by 1 from 11, and a proposal to raise the annual cap on director compensation from ¥500 million to ¥750 million.

Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
2.5
¥100 million (increase in the director compensation cap)
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (51st)
2026
Jun 23
Date and time22 days from this disclosure to the meeting
Matters for resolution2 items
  1. Election of 12 Directors

  2. Revision of the director compensation cap

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee12 candidates, including 1 new candidate; 7 of the 12 are outside directors
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (51st)
Date and time10:00 a.m. on Tuesday, 23 June 2026
Matters for resolutionProposal No. 1: Election of 12 Directors, Proposal No. 2: Revision of the director compensation cap
Shareholder ProposalNo
Director nominee12 candidates, including 1 new candidate; 7 of the 12 are outside directors
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The increase in the number of directors is intended to strengthen governance in response to further globalization going forward. The revision of the compensation cap is intended to address recent economic conditions and secure and retain appropriate personnel capable of responding to further globalization.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Shareholder Meeting Materials | JCR Pharmaceuticals Co.,Ltd. (4552) timely disclosure | Komori